Insights Into Acute Lymphoblastic Leukemia Midwest (ALL)
Perspectives on current treatment practices in the northwest region of the US regarding adult and AYA ALL, the role of MRD, and current treatment practices regarding relapsed disease
Northwest – November 17, 2020
Faculty Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
REPORT SNAPSHOT
Insights on the following topics were obtained
- Impact of risk stratification, age, and biomarkers on treatment (adult vs AYA, Ph+ vs Ph– vs Ph-like)
- Differentiation of TKIs for Ph+ patients
- Use of hyper-CVAD vs multiagent chemotherapy
- Defining the appropriate patient for pediatric-inspired regimens
- Response assessment and MRD monitoring
- Management of MRD-positive disease
- Inclusion of monoclonal antibodies into therapy (inotuzumab ozogamicin, blinatumomab)
- Duration of response, impact of reinduction, and patient selection for transplant
- CAR T therapy
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- A moderated roundtable discussion focusing on treatment of ALL was held on November 17, 2020
- The group of advisors comprised 9 community oncologists from the northwest (USA)
- Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion
